Showing results (311-320 of 6,497) with videos related to
Sort By:
Pageof 650
Human Vaccines & Immunotherapeutics|June 5, 2013
Effectiveness of seasonal influenza vaccine against clinically diagnosed influenza over 2 consecutive seasons in children in Guangzhou, China: a matched case-control studyQing He, Jianxiong Xu, Xi Chen, et al.Human Vaccines & Immunotherapeutics|June 5, 2013
Potential therapeutic anti-tumor effect of a Salmonella-based vaccineSun-Young Chang, Yeon-Jeong Kim, Hyun-Jeong KoHuman Vaccines & Immunotherapeutics|April 9, 2013
Hypothesis driven development of new adjuvants: short peptides as immunomodulatorsJessica C Dong, Gary P KobingerHuman Vaccines & Immunotherapeutics|April 9, 2013
CpG adjuvant enhances the mucosal immunogenicity and efficacy of a Treponema pallidum DNA vaccine in rabbitsFeijun Zhao, Shuangquan Liu, Xiaohong Zhang, et al.Human Vaccines & Immunotherapeutics|August 1, 2013
Antibiotic-free production of a herpes simplex virus 2 DNA vaccine in a high yield cGMP processJared Nelson, Stephen Rodriguez, Neil Finlayson, et al.Human Vaccines & Immunotherapeutics|August 1, 2013
Expression at a 20L scale and purification of the extracellular domain of the Schistosoma mansoni TSP-2 recombinant protein: a vaccine candidate for human intestinal schistosomiasisElena Curti, Clifford Kwityn, Bin Zhan, et al.Human Vaccines & Immunotherapeutics|August 1, 2013
Identification of the factors that result in obviousness rulings for biotech patents: an updated analysis of the US Federal Circuit decisions after KSRFangyu Lin, Shyh-Jen WangHuman Vaccines & Immunotherapeutics|June 20, 2013
Immunogenicity and safety of Intanza(®)/IDflu(®) intradermal influenza vaccine in South Korean adults: a multicenter, randomized trialSang Hoon Han, Jun Hee Woo, Francoise Weber, et al.Human Vaccines & Immunotherapeutics|June 21, 2013
Randomized, placebo-controlled phase II trial of heat-killed Mycobacterium vaccae (Longcom batch) formulated as an oral pill (V7)Yuri V Efremenko, Dmytro A Butov, Natalia D Prihoda, et al.Human Vaccines & Immunotherapeutics|June 22, 2013
Hexavalent IPV-based combination vaccines for public-sector markets of low-resource countriesKutub Mahmood, Sonia Pelkowski, Deborah Atherly, et al.Pageof 650